The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of California

University of Georgia Research Foundation, Inc.

Baylor College of Medicine

The University of North Carolina at Charlotte

Mathias D Viard

Kirill Andreevich Afonin

Bruce Allen Shapiro

Robert P Blumenthal

Yossef Raviv

Anu Puri

Luc Jaeger

Stephen Mark Tompkins

Robert Jeff Hogan

Wojciech Kasprzak

Amit Joshi

Eckart Bindewald

Justin R Halman

Angelica N Martins

Arti N Santhanam

Julie M Belanger

Darayash B Tata

Julian W Bess, Jr

Eckart H U Bindewald

Marina A Dobrovolskaia

Angelica Nascimento Martins

Embodiments of vesicles comprising embedded cytotoxic agents are disclosed, as well as methods of making and using the vesicles. Pharmaceutical compositions including the vesicles also are disclosed. The vesicles include a binary lipid bilayer surrounding a cavity, wherein the vesicle binary lipid bilayer includes (i) a non-bilayer forming lipid (or combination of non-bilayer forming lipids) and a PEGylated lipid; and (i) a cytotoxic agent embedded within the vesicle wall.

Binary lipid bilayer-containing vesicles comprising embedded cytotoxic agents and methods of making and using the same

The description provides a molecular switch comprising at least two nanoparticles, wherein a first nanoparticle comprises DNA and/or RNA oligonucleotides, and a second nanoparticle which is complementary to the first nanoparticle comprises reverse complementary DNA and/or RNA oligonucleotides of the first nanoparticle; wherein the complementary nanoparticles interact under physiological conditions leading to thermodynamically driven conformational changes in the first and second nanoparticles leading to their re-association to release one or more duplexes comprising said DNA and/or RNA oligonucleotides and the reverse complementary DNA and/or RNA oligonucleotides, and wherein the nanoparticles are not rings and have no single stranded toeholds.

Functionally-interdependent shape switching nucleic acid nanoparticles

The instant invention provides RNA nanocubes, DNA nanocubes and R/DNA chimeric nanocubes comprising one or more functionalities. The multifunctional RNA nanocubes are suitable for therapeutic or diagnostic use in a number of diseases or disorders.

Triggering RNA interference with RNA-DNA and DNA-RNA nanoparticles

The instant invention provides RNA nanoparticles and R/DNA chimeric nanoparticles comprising one or more functionalities. The multifunctional RNA nanoparticles are suitable for therapeutic or diagnostic use in a number of diseases or disorders.

Multifunctional RNA nanoparticles and methods of use

Embodiments of photoactivatable, lipid-based nanoparticles are disclosed, as well as methods of making and using the nanoparticles. Pharmaceutical compositions including the nanoparticles also are disclosed. The lipid-based nanoparticles include a vesicle wall surrounding a cavity, wherein the vesicle wall includes (i) a lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DCPC), dipalmitoylphosphatidylcholine (DPPC), and (ii) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer. The nanoparticles may further include an agent within the cavity.

Photoactivatable lipid-based nanoparticles as vehicles for dual agent delivery

Auto-recognizing therapeutic R/DNA chimeric nanoparticles (R/DNA NP) are described that are pairs of DNA/RNA hybrids where the DNA molecules have complementary toehold sequences that promote the re-association of the R/DNA NPs when mixed resulting in the formation of RNA/RNA duplexes that act as siRNAs.

Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP)

The invention involves inactivation of viral populations by treating the viral populations with a compound to crosslink proteins in the viral membrane, UV irradiation and further inactivation of the viruses using detergent(s). According to the invention, this method preserves the native structure of viral epitopes so that the inactivated viral preparations can be used in immunological compositions that will inhibit and/or prevent viral infection when administered to an animal.

Cellular and viral inactivation

The invention provides compositions of inactivated influenza virus that can be used as vaccines and immunological compositions useful for inhibiting, preventing and treating influenza.

Inactivated influenza virus compositions

The invention provides compositions of inactivated viruses, bacteria, fungi, parasites and tumor cells that can be used as vaccines. Methods for making such inactivated viruses, bacteria, fungi, parasites and tumor cells are also provided.

Growing community of inventors

Frederick, MD, United States of America

Mathias D Viard